Aquestive Therapeutics (AQST) Fair Value & DCF
Score
AQST fair value $6.06. Price $3.91. Price is 36% below fair value.
Worked example
Cash-flow value. Starting free cash flow is $0.05 a share. Years 1 to 5 grow at 11.14%. Years 6 to 10 fade that rate in a straight line to 3% terminal growth. The discount rate is 12.00% (beta 1.49, capped at 12%). It is beta-adjusted and capped at 12%. The cash-flow value is $0.87 a share.
Earnings value. Next-twelve-months earnings per share of $0.38 times 30.00 is $11.25. The peer group is Healthcare, 75 companies worth at least $10 billion. This stock has no 10-year median P/E, so the peer median of 30.7 is kept between 8 and 30, which is 30.00.
Fair value is the average of the two, $6.06. The price is $3.91, which is 35.5% below fair value.